Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LAMIVUDINE; STAVUDINE; NEVIRAPINE

LAMIVUDINE; STAVUDINE; NEVIRAPINE

Standard Dose
150MG; 30MG; 200MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE; STAVUDINE; NEVIRAPINE is listed in Drugs@FDA under application 021969 (NDA).

Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; STAVUDINE; NEVIRAPINE Form and strength TABLET; ORAL - 150MG; 30MG; 200MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2006-11-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE; STAVUDINE; NEVIRAPINE is listed in Drugs@FDA under application 021969 (NDA). Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; STAVUDINE; NEVIRAPINE Form and strength TABLET; ORAL - 150MG; 30MG; 200MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2006-11-17 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.